AAB Calls For Inclusion of Biotech Provisions in the FY26 National Defense Authorization Act (NDAA)
- RB Coleman
- Oct 27, 2025
- 1 min read
The AAB joined with 32 other leaders in the U.S. biomanufacturing sector calling for the inclusion of the biotechnology provisions in the Fiscal Year 2026 National Defense Authorization Act (NDAA). The letter notes that the National Security Commission on Emerging Biotechnology (NSCEB) concluded that:
"Advances in biotechnology represent a paradigm shift in how conflicts can be fought and won. The countries that seize the moment will retain or achieve superpower status. Those that fail to do so will not only fall behind but also become vulnerable to the use of biotechnology against them."
Congress is starting the process of reconciling the House and Senate-passed versions of the FY2026 NDAA. The letter calls for all provisions to be included in the final bill.
What a fantastic and well-researched post!
What's particularly notable is the growing body of evidence around cardiovascular benefits. The SELECT trial demonstrated that semaglutide significantly reduced major adverse cardiovascular events in overweight patients without diabetes, suggesting that the benefits of GLP-1 receptor agonist therapy extend well beyond glycemic control and weight loss. Reductions in systemic inflammation, improvements in lipid profiles, and positive effects on blood pressure have all been documented. For patients who carry significant cardiometabolic risk, these incretin-based therapies represent a meaningful step forward in preventive medicine.
The emergence of microdosing protocols for GLP-1 medications is another area generating significant clinical interest. Some practitioners are exploring whether lower doses can provide meaningful metabolic benefits with a reduced side effect…